scholarly journals Response to: ‘Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’’ by Bandayet al

2021 ◽  
pp. annrheumdis-2021-219919
Author(s):  
Peter Nash ◽  
Josef S Smolen
Keyword(s):  
Kinase Inhibitors ◽  
Consensus Statement ◽  
Inflammatory Diseases ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated

scholarly journals Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

2020 ◽  
Vol 80 (1) ◽  
pp. 71-87 ◽  
Author(s):  
Peter Nash ◽  
Andreas Kerschbaumer ◽  
Thomas Dörner ◽  
Maxime Dougados ◽  
Roy M Fleischmann ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Consensus Statement ◽  
Task Force ◽  
Inflammatory Diseases ◽  
Steering Committee ◽  
Janus Kinase ◽  
Expert Committee ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated

ObjectivesJanus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.MethodsExisting data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration.ResultsThe Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale.ConclusionThe consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.

scholarly journals 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

2021 ◽  
pp. annrheumdis-2021-221366
Author(s):  
Alessia Alunno ◽  
Aurélie Najm ◽  
Pedro M Machado ◽  
Heidi Bertheussen ◽  
Gerd-Rüdiger R Burmester ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Task Force ◽  
Inflammatory Diseases ◽  
Janus Kinase ◽  
Therapeutic Approaches ◽  
Janus Kinase Inhibitors ◽  
Immunosuppressed Patients ◽  
Critical Patients ◽  
Immunomodulatory Therapies ◽  
Robust Evidence

ObjectivesTo update the EULAR points to consider (PtCs) on the use of immunomodulatory therapies in COVID-19.MethodsAccording to the EULAR standardised operating procedures, a systematic literature review up to 14 July 2021 was conducted and followed by a consensus meeting of an international multidisciplinary task force. The new statements were consolidated by formal voting.ResultsWe updated 2 overarching principles and 12 PtC. Evidence was only available in moderate to severe and critical patients. Glucocorticoids alone or in combination with tocilizumab are beneficial in COVID-19 cases requiring oxygen therapy and in critical COVID-19. Use of Janus kinase inhibitors (baricitinib and tofacitinib) is promising in the same populations of severe and critical COVID-19. Anti-SARS-CoV-2 monoclonal antibodies and convalescent plasma may find application in early phases of the disease and in selected subgroups of immunosuppressed patients. There was insufficient robust evidence for the efficacy of other immunomodulators with further work being needed in relation to biomarker-based stratification for IL-1 therapyConclusionsGrowing evidence supports incremental efficacy of glucocorticoids alone or combined with tocilizumab/Janus kinase inhibitors in moderate to severe and critical COVID-19. Ongoing studies may unmask the potential application of other therapeutic approaches. Involvement of rheumatologists, as systemic inflammatory diseases experts, should be encouraged in clinical trials of immunomodulatory therapy in COVID-19.

scholarly journals APPLICATION OF JANUS-KINASE INHIBITORS IN THE TREATMENT OF ALOPECIA AREATA (LITERATURE REVIEW)

2019 ◽  
Vol 22 (1-2) ◽  
pp. 61-64
Author(s):  
Anfisa A. Lepekhova ◽  
L. M Chernyavskaya
Keyword(s):  
Literature Review ◽  
Mechanism Of Action ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Targeted Drugs ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated ◽  
Adults And Children

Based on the analysis of data from modern foreign sources current information about using of Janus-kinase inhibitors, in particular, tofacitinid and ruxolitinid, for the treatment of alopecia areata in adults and children, in the presence of a lesion of the scalp and other areas (eyebrows, eyelashes) is shown. The information about the mechanism of action of Janus-kinase inhibitors, the efficacy and safety of their use, possible methods of use, prospects for further research in the treatment of alopecia areata using targeted drugs is presented. The pathogenetic rationale for the possibility of using this group of drugs for treating immune-mediated diseases, for instance, alopecia areata is described.

Hijaking the SARS-CoV-2 Cytokinopathy: Janus Kinase Inhibitors for Moderate to Severe COVID-19

2020 ◽  
Author(s):  
Christine Won ◽  
William Damsky ◽  
Inderjit Singh ◽  
Phillip Joseph ◽  
Astha Chichra ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document